Introduction

Vital to investigating the immune system’s spontaneous responses to cancer as a basis for designing immunotherapy has been a resurgence in patient studies and animal models that support the immunosurveillance hypothesis. Proposed in 1970 by Burnet and Thomas, the term ‘immunosurveillance’ implies that many tumors occur but never progress to clinical disease because they are cleared naturally by the immune system [1]. This hypothesis postulates that cancer can overcome the individual response when it evolves to evade normal immune defenses, or when the immune system becomes compromised.

Immunosurveillance was difficult to test experimentally when originally proposed and remained primarily a hypothesis for many years. This was partly due to the lack of an appropriate mouse model. The evidence that the immune system suppresses tumor development became ultimately quite clear as differences between mouse strains were better understood and reagents that addressed the role of cytokines and other immune mediators became available [1]. For example, IFNγ and perforin were shown to be necessary for tumor rejection in mice. When IFNγ responses were eliminated, such as in IFNγ receptor or STAT1-deficient mice, or with monoclonal blocking antibody to IFNγ, susceptibility to methylycholanthrene-induced tumors was increased. These same IFNγ-unresponsive mice crossed with p53 tumor
suppressor-deficient mice showed an increase in tumor burden when compared to mice with p53 deficiency alone, implying that IFNγ is necessary for continued protection against tumors. Perforin-deficient mice demonstrated a similar susceptibility to tumor formation compared to controls [1].

Spontaneous murine tumor models based on transgenes that carry known oncogenic mutations, such as Kras, INK4A and PTEN, are making it possible to determine what early steps in tumor development are subject to immunosurveillance [2, 3]. The ability to time and examine early neoplasia in mice will allow an evaluation of which immune effector cells, cytokines, and other immune components are induced and necessary for eradication of transformed cells.

**Immune Response to Tumors**

With the acceptance of the immunosurveillance hypothesis it has become apparent that giving the immune system the appropriate stimulus will allow it to overcome evasion and eliminate tumors. Of course, the time most patients are diagnosed with a malignancy, they have been harboring the tumor for some time and are usually immunosuppressed [4]. This is likely to be the reason that early detection and treatment of disease result in the best clinical prognosis as treatment occurs before immunosuppressive effects have developed fully [5, 6]. Increasingly, solutions to the cancer problem are focused on immunoprevention at early stage immunotherapies (fig. 1). The most recent breakthrough in this regard is the multivalent vaccine against human papilloma virus that prevents viral infection and thus cervical cancer [7].

The immune responses that are most effective against tumor growth are those generated through a well-balanced and well-timed interplay between the innate and the adaptive immune system. Antigens are presented by activated dendritic cells (DCs) to CD4 T cells, which in turn coordinate CD8 cytotoxic T lymphocytes (CTL) and antibody production by B cells [8]. In some cases the contribution of activated NK and NKT cells, which like CTLs use perforin and granzymes to destroy their targets, have been shown to be necessary for tumor control [9, 10].

When the balance between the innate and the adaptive immunity is skewed in favor of innate immune responses, this can also exacerbate disease and facilitate tumor growth. Some components of the innate immune response found in tumors, such as macrophages and mast cells, have been correlated with increased tumor growth and metastasis [11, 12]. Upon activation, these cells release oxidants, prostaglandins, cytokines, and other components that directly and indirectly cause tissue destruction and remodeling. Peripheral granulocytes from patients with metastatic adenocarcinomas have been shown to release hydrogen peroxide which in turn impairs T cell function [4]. Tumor-infiltrating macrophages can secrete matrix metalloprotease-9 (MMP9) that releases VEGF from extracellular matrix stores, increasing angiogenesis at the tumor site and suppressing DC function [13].

Chronic inflammation, characterized by sustained activation of many players in the immune system, is suspected to drive premalignant lesions into fully malignant states. Inflammation can occur in response to chronic infections with a diverse array of pathogens such as hepatitis viruses or Helicobacter pylori [14]. Sustained inflammation can also be the result of an individual’s inability to restore immune homeostasis after infection. The increased expression of COX-2, an enzyme in the prostaglandin biosynthetic pathway, has been correlated with colorectal cancer [15]. Similarly, blocking the function of this enzyme with nonsteroidal anti-inflammatory drugs has correlated with decreased cancer risk in humans, particularly in colon cancer [16]. Consequently, halting chronic inflammation may restore the immunosurveillance mechanisms necessary to control transformation and neoplastic growth.

In contrast to chronic inflammation, acute inflammation has been shown to eliminate some cancers. One current therapy based on the principle of eliciting strong acute inflammation uses bacillus Calmette-Guérin (BCG), an attenuated strain of Mycobacterium tuberculosis, to treat bladder cancer [17]. Intravesicular instillation of the bacterium into the bladder activates resident DCs, which then increases antigen presentation and cytokine production. The first immune-based therapy that used acute inflammation to fight against cancer was the administration of ‘Coley’s toxins’. William Coley had observed that patients with sarcomas that also suffered from erysipelas, a severe bacterial skin infection coupled with a fever, experienced remission of their tumors. Based on this evidence, he subsequently injected patients with a combination of heat-killed Streptococcus and Serratia marcescens [18–20]. Now it is understood that the bacterial products Coley injected provided the ‘danger signals’ that induced DCs to give efficient costimulation to both the innate and the adaptive arms of the immune system [21]. Additionally, the increased inflammation and necrotic tissue at the site of the sarcoma, where the injection of bacterial products was
made, would have increased the number and efficiency of antigen-presenting cells (APCs). Without antigen presentation and strong costimulation, some tumors can progress unchecked by the immune system.

The above examples describe instances where tumor progression or tumor rejection are byproducts of the immune response activated through dangers other than the tumor itself. While one can learn a great deal from studying these processes, especially regarding the immune effectors and their targets on tumor cells, only an elicited tumor-specific immune response can be turned into a therapy with a reproducible outcome. For generating the ultimate antitumor effector cells, tumor-specific antigens need to be presented on professional APCs. The most potent of these are DCs, which are being targeted in vivo or manipulated in vitro for use as adjuvants in numerous current therapies [8].

Fig. 1. The difference between immunoprevention and immunotherapy is in the timing and the expected outcome. a Immunoprevention uses a vaccine in an individual at risk for developing cancer, to generate immunologic memory that prepares the immune system to detect and eliminate future premalignant lesions. b Conversely, immunotherapy addresses the disease after it is already diagnosed. Immunotherapies can take the form of vaccines or monoclonal antibody therapies among others. Depending on when the disease is detected, immunotherapies can be given early (neoplastic lesions) or late (primary and metastatic tumors) in the disease process. Due to limitations in detecting neoplastic lesions most immunotherapies are given at later stages of disease and show success primarily in the setting of a minimal tumor burden.
Tumor Immunotherapy

Several approaches to target tumors are currently being pursued that exploit the specificity of the immune system. The first among these is the vaccine approach. Traditionally vaccines have been exceptionally effective at priming the immune system to protect against infectious diseases. Based on this successful protection against infectious disease, vaccines may also be effective at priming an individual’s immune system to control their own malignancies. Choosing an adjuvant and target antigen has proven challenging and success is likely to result from polyvalent approaches that utilize as many aspects of the immune response as possible. Timing is also important; the most effective vaccination against pathogens occurs before infection and this is likely to be most effective for malignancies as well [22]. Therapeutic vaccines that treat patients after diagnosis of malignant disease are currently being tested [23]. However, the immense success of the one prophylactic cancer vaccine that immunizes against human papilloma virus and protects against cervical cancer has reinforced that prevention is better than therapy during disease [24]. Additional evidence that immunologically relevant events protect against developing malignancies later in life would argue that such prophylaxis is the route to follow. One recent report from our laboratory demonstrates that bone breaks, contraceptive use, mastitis, and pelvic surgeries are protective against ovarian cancer with the hypothesis that the anti-MUC1 responses induced during those episodes provide protection from malignancies [25].

Antitumor Vaccines

When vaccinating an individual, the goal is to provide an effective immune memory response to antigen challenge. Whether the targeted antigen comes from a pathogen or is from a transformed cell, the same principles apply. There are three main questions to answer when developing a vaccine: what antigen(s) to target, what is the ideal time and route of vaccine delivery, and what adjuvant to use in order to elicit a desired type of immune response?

Tumor Antigens

When vaccinating against an infectious agent, the antigens used are foreign to the host immune system and thus are free from many of the complicating concerns of cancer antigens being self-antigens. Because malignant transformation comes from the ‘host material’ immune responses against many of the antigens expressed on tumors are either subject to self-tolerance or potentially could result in autoimmunity if tolerance is broken. However, there are several classes of antigens that make good potential targets for use in vaccines directed against tumors because their restricted expression or expression pattern is characteristic of tumors rather than healthy tissue, and thus not hindered by self-tolerance or prone to generate adverse autoimmune effects.

Some selected characteristics of tumor antigens that make them useful targets for immunotherapy are: (1) common expression on a variety of carcinomas thus making the vaccine more broadly applicable, (2) stable expression through different stages of tumor development so that stem cells, progenitor cells and mature tumor cells can all be targets of the elicited immune responses, and (3) indispensable for tumor survival and thus not susceptible to immunoediting [26]. Many tumor antigens identified to date have these characteristics. They belong to several categories that include products of mutated genes, viral antigens, differentially expressed antigens and tissue-restricted antigens. Most tumor antigens characterized to date are differentially expressed antigens and tissue-restricted antigens.

Differentially Expressed Tumor Antigens

Early attempts at understanding tumor immunity were based on the assumption that the immune system can only recognize molecules that are expressed in tumors as a result of many oncogenic events, and not on normal cells. However, this assumption proved incorrect and the majority of molecules identified as human tumor targets were found to have the same gene and protein sequence as the normal cells that gave rise to the tumor. The differences seen by the immune system were instead quantitative, such as antigenic overexpression, and/or qualitative, such as aberrant posttranslational modifications. We describe below three well-known tumor antigens that belong to this category and also fulfill the criteria for good vaccine candidates.

Human mucin 1 (MUC1) has been studied as a tumor antigen and target for immunotherapy for over a decade. In healthy tissues, MUC1 is expressed at low levels on the apical surface of ductal epithelial cells as a heavily glycosylated transmembrane protein. Conversely, in the majority of human adenocarcinomas, MUC1 is overexpressed and hypoglycosylated [27, 28].

Many patients with MUC1+ tumors have low levels of specific CTLs [29, 30] and low antibody titer [31, 32], and
both types of responses have been shown to be specific for the polypeptide core of MUC1. Even though the patients have detectable tumor MUC1-specific immune responses, most succumb to their disease. As a preclinical model, we have shown the safety and immunogenicity of three different MUC1-based vaccines in the MUC1-transgenic mouse [33]. In addition, we showed an important difference in the anti-MUC1 responses when MUC1 is expressed as a self-molecule as compared to the wild-type mouse where it is not endogenously expressed. We and others have attributed this difference to the hypersensitiveness in the MUC1-specific CD4 T helper cell compartment [33–35]. A new opportunity for MUC1 tumor vaccine preclinical studies has emerged with the development of spontaneous tumor models in the MUC1-transgenic mouse [36–38]. These will allow a more physiological comparison to humans concerning the effectiveness of MUC1-specific vaccines. In addition to mouse studies, we have used a MUC1 peptide with adjuvant LeIF (Leishmania braziliensis-derived protein) vaccine in nonhuman primates that was safe, tolerable, and capable of inducing an anti-MUC1 cellular immune response [39]. More recently we completed a phase I trial using a vaccine composed of the MUC1 100-amino acid core polypeptide with the adjuvant SB-AS2 (monophosphoryl A, purified saponin and an oil-water immersion) to treat pancreatic cancer patients after tumor resection [40]. This trial showed the vaccine to be safe and to have the potential of inducing MUC1-specific immune responses.

HER2/neu (also known as Erb-B2) is expressed as a 185-kDa glycoprotein surface receptor, member of the epidermal growth factor family of tyrosine kinase receptors. HER2/neu functions in cell cycle regulation and its expression on healthy tissues are low [41]. Numerous adenocarcinomas show HER2/neu overexpression, including those of the breast, ovary, colon, prostate, and lung. HER2/neu overexpressing tumors have been characterized as being more aggressive and linked to shorter patient survival [42].

A finding that indicated the potential of HER2/neu as a vaccine candidate and target for immunotherapy was the presence of preexisting anti-HER2/neu immune responses in cancer patients with HER2/neu-overexpressing tumors. As in the case of MUC1 immunity, even though the response is too low to effectively clear the established tumor, it indicates that the adaptive immune repertoire had not been depleted of HER2/neu-specific B and T cells through tolerance mechanisms to self-proteins [43].

The most notable HER2/neu-based immunotherapy is the humanized anti-HER2/neu antibody Herceptin® (trastuzumab). Originally generated and studied in mice, Herceptin is currently FDA approved as it has been shown to confer longer disease-free survival in HER2/neu+ breast cancer patients [44, 45]. In addition to Herceptin, invoking cellular anti-HER2/neu responses has been shown to control tumor growth in spontaneous breast cancer models in HER2/neu-transgenic mice [46, 47] and breast and ovarian cancer patients [48].

Cyclin B1 was recently identified to be a tumor antigen by our group and shown to be constitutively overexpressed in the cytoplasm of tumor tissue and tumor cell lines [49]. Under normal conditions cyclin B1 is transiently expressed in the nucleus as a mediator of the G2-M phase transition in the cell cycle. Our group and others have shown cyclin B1 expression to be regulated by p53, and overexpression in transformed tissue has been associated with the deregulation of this well-studied tumor suppressor gene [50, 51]. Cyclin B1 deregulation has been associated with oncogenesis as well as poor prognosis [52].

Cyclin B1 overexpression and anti-cyclin B1 immune responses have been identified in patients with various adenocarcinomas, including those of the colon, pancreas, breast and lung [49, 53–55]. Current preclinical studies on human cyclin B1 have been limited to human tissue samples and cell lines. Our group has begun preliminary work examining human cyclin B1 immune responses and mouse cyclin B1 antitumor vaccines (unpubl. data) using the p53–/– mouse model of spontaneous carcinoma [56].

**Tissue-Restricted Antigens**

In contrast to differentially expressed antigens, it was gradually recognized that some tumor antigens were not expressed on the normal tissue that tumors originated from. These tumor antigens are referred to as tissue-restricted antigens because their expression in healthy individuals is either restricted to fetal development, before the adaptive immune system completely matures, or restricted to immune privileged sites and not accessible to immune surveillance. As such, they make excellent vaccine targets, as previously arising tolerance and autoimmunity are less likely to be complicating factors.

Identified in 1965 [57], carcinoembryonic antigen (CEA) has been widely studied for its role as a tumor marker and tumor antigen. CEA is a 180-kDa glycoprotein, found both at the cell surface and in a secreted form. CEA is categorized as an oncofetal antigen, expressed at

---

Tumor Antigens for Immunotherapy

Int Arch Allergy Immunol 2007;142:179–189
high levels in the fetal gut during development, and more recently CEA was found in some cases to be expressed at low levels in the adult colon [58, 59].

A clear function of CEA in healthy and transformed tissue has yet to be defined. Studies have indicated a role as an intercellular adhesion molecule [60, 61] and when overexpressed, an inhibitor of anoikis [62], a form of apoptosis triggered by insufficient cell-matrix contacts [63]. In addition, CEA overexpression on neoplastic tissue has a role in tumor progression and metastasis [64]. Tumor CEA has an aberrant glycosylation pattern [65, 66] and is overexpressed on a large number of adenocarcinomas, including 90% of gastrointestinal, colorectal, and pancreatic cancers, 70% of non-small-cell lung cancers, and 50% of breast cancers [67]. The tumor expression profile of CEA on a large number of different adenocarcinomas, in combination with its possible role in tumor progression and metastasis, makes CEA a promising target for immunotherapy.

CEA-transgenic mice have been used for preclinical studies of various forms of CEA-targeted immunotherapies. Vaccines using recombinant pox viral vectors (vaccinia, ALVAC, fowlpox), DCs, or anti-idiotype antibodies have been shown to generate anti-CEA-mediated protective immunity to subsequent tumor challenge [67]. The anti-CEA immune response was also demonstrated in HLA-A2:CEA double-transgenic mice [68]. Importantly, these studies showed that intrinsic tolerance to CEA could be overcome in the CEA-transgenic mice without causing any adverse autoimmune effects [69]. Following the animal studies, several human studies and phase I trials have been completed showing safety as well as induction of anti-CEA immune responses and antitumor effects [70].

The NY-ESO-1 antigen falls into a subcategory of tissue-restricted antigens, the cancer/testis antigens. Expression of these antigens is normally restricted to germ cells and trophoblasts but is also expressed on a wide variety of cancers. Over 40 antigens have been identified as cancer/testis antigens with NY-ESO-1 having been the most studied to date due to its strong tumor-specific immunostimulatory capacity [71]. Recently completed clinical studies using an NY-ESO-1 and ISCOMATRIX adjuvant vaccination strategy showed the vaccine to be well tolerated, safe, and capable of inducing potent immune responses [72], as well as possible clinical responses [73]. Currently a number of clinical trials treating various cancer types are being conducted using differing combinations of NY-ESO-1 and adjuvants [74].

In recent years there has been a trend for antitumor vaccines to include multiple tumor antigens [75, 76]. Considering the rapid growth rate and genetic instability of growing malignancies, combining multiple antigens into a single vaccine will help to prevent development of tumor antigenic loss variants [77, 78]. In addition to addressing tumor antigenic loss variants, other tumor escape mechanisms need to be considered. These mechanisms can include activity of T regulatory cells, expression of regulatory molecules, and/or production of anti-inflammatory cytokines [79, 80].

**Vaccine Design**

Currently most therapeutic vaccines use single antigens and most are chosen for their ability to elicit cytotoxic T cell responses [81]. There is evidence from animal studies, however, that for full tumor control involving establishment of a strong memory response, more may be needed than just an effector T cell response [82]. A vaccine that can elicit a more comprehensive immune response involving both helper and cytotoxic T cells, as well as a strong antibody response, is likely to be the vaccine that can provide effective tumor control. This type of vaccine will require either multiple tumor antigens or multiple epitopes derived from the same antigen, as well as adjuvants that stimulate good innate immune responses and production of cytokines important for supporting both arms of the adaptive immune system. In our own studies of MUC1 vaccines we have favored a long peptide (100 amino acids) as antigen because it contains epitopes recognized by CTL, helper T cells [83, 84] and B cells [32]. The use of longer peptides is now advocated by other groups as well [85].

How a vaccine is administered is another important consideration in vaccine design. We discussed above how important timing relevant to disease occurrence is likely to be in vaccination. The route of entry for antigens and associated adjuvants is equally important [86]. Traditionally, vaccines have been injected intramuscularly, regardless of the site of cancer. This is suboptimal in two very important ways. Intramuscular injection is likely to elicit systemic immunity. Cancers that occur in mucosal sites, particularly those involving mucosal epithelium might require a good mucosal immune response instead and thus mucosally administered vaccines would be a better strategy. The microenvironment of gastric and gynecologic mucosa is a tolerogenic one that adenocarcinomas evolve within, and to target them appropriately a mucosal route of administration of antigen and potent mucosal adjuvants are necessary [86]. An example of a
successful mucosal vaccine is FLUMIST™, an intranasal vaccine against influenza. This vaccine as well as other effective vaccines against pathogens can inform cancer vaccine design. Adjuvants were mentioned several times above in connection with vaccine design. The reason is that administering antigens that do not activate APCs and induce high levels of costimulatory molecules would simply induce tolerance.

One example of a promising adjuvant is heat-labile toxin of Escherichia coli (LT). When given topically over the site of antigen injection, LT is believed to activate APCs found in the skin, Langerhans cells, which take up antigens depending on the presence of proinflammatory cytokines and CD40 ligation [8]. Targeting of the endocytic receptor DEC-205 with an antigen-antibody conjugate has also capitalized on this pathway to target a more complete immune response [90].

**Therapy with Monoclonal Antibodies**

The use of humanized or chimeric monoclonal antibodies has been particularly successful against specific types of cancers. Antibody binding to tumor cells can cause direct killing through antibody-dependent cellular cytotoxicity, complement-mediated lysis, or through inhibition of target cell proliferation [91]. As discussed earlier, breast cancers that overexpress HER2/neu are susceptible to the humanized antibody Herceptin [92].

Monoclonal antibodies to tumor antigens can also deliver a chemotherapeutic agent such as a radiolabeled isotope. Monoclonal antibodies to CEA linked to both yttrium-90 and iodine-131 have been used with limited efficacy [93, 94]. However, this approach has been very successful with B cell lymphomas treated with a monoclonal antibody to CD20 linked to iodine-131 (Bexxar®) [95, 96]. Administration of the same chimeric antibody, rituximab, with a chemotherapeutic cocktail containing cyclophosphamide, doxorubicin, vincristine, and prednisone prolongs event-free survival in patients with B cell lymphoma [97]. Rituximab has been successful in treating a number of B cell-mediated lymphomas and is now also approved for use in rheumatoid arthritis.

**Preclinical Models**

The most commonly used animal models in tumor immunology research are mice. Since the majority of tumor-associated antigens are derived from self-antigens, it is important to test antitumor vaccines in mice that also express the tumor antigen as a self-antigen. This need led to the engineering of mice expressing human tumor antigens as transgenes, for example MUC1- and CEA-transgenic mice [69, 98]. Using the transgenic mice one can answer questions about the efficacy of the therapy, endogenous immune tolerance mechanisms, as well as possible autoimmune damage to healthy tissue.

Until recently, the majority of studies assessing the effects of in vivo tumor immunotherapy involved postvaccination tumor challenge by injection of a cultured tumor cell line. Although this has demonstrated tumor-associated antigen-specific protection, these models do not represent human disease. To better mimic the interaction of the innate or vaccine-elicited immune response with the slow progression of carcinoma that occurs in humans, spontaneous tumor models have been developed [2, 3, 99–102]. One of the newest is a model based on a conditionally expressed mutant of Kras [103]. The fact that...
Kras is an oncogene that is commonly mutated in human tumors makes the model very attractive to study neoplastic growth and the immune responses right from the start of cellular transformation. More specifically, spontaneous tumor models allow one to follow the appearance and role of specific tumor antigens in oncogenesis and disease and the immune response against it.

**Conclusion**

Each cancer can be as unique as the patient that suffers from it but there are also antigenic similarities that can be exploited for immunotherapy. As the individual’s immune system and neoplasm coexist for a prolonged period of tumor development, each exerts influence on the other. Two promising areas of tumor immunotherapy are vaccines and monoclonal antibody-based therapies. An important difference between these two therapies is that monoclonal antibodies are limited to the presence of disease, whereas tumor antigen-based vaccines can serve either as a tumor immunotherapy (concurrent with disease) or as an immunoprevention treatment (for individuals at high risk for cancer). The best-case scenario would be to prevent disease from occurring, by using prophylactic vaccination. This has worked exceptionally well in the case of infectious disease. Development of many technologies that identify early disease and/or individuals at high risk for disease, combined with the improved understanding of the requirements for greater efficacy and safety of antitumor immune responses, has brought cancer immunoprophylaxis into the mainstream of cancer prevention efforts.

**References**


63 Frisch SM, Screaton RA: Anoikis mecha-


dovic L, McCluskey J, Old LJ, Davis ID, Ce-


74 Nicolau T, Ebert L, Davis ID, Robson N, Klein O, Maraskovsky E, Chen W, Ceon J: Directions in the immune targeting of can-

75 Valmorri D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Lienard F, Lejeune F, Cerottini JC, Romero P, Speiser DE: Simultaneous CD8+ T cell responses to multiple tumor an-


77 Manjili M, Arnouk H, Knutson K, Kmieciak M, Disis M, Subjeck J, Kazim A: Emergence of immune escape variant of mammary tu-
mors that has distinct proteomic profile and a reduced ability to induce ‘danger signals’. Breast Cancer Res Treat 2006;96:233.

78 Gajewski TF, Fallarino F, Ashikara A, Sherman M: Immunization of HLA-A2+ mela-
noma patients with MAGE-3 or MelanA peptide-pulsed allogeneic peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001;7:895S–903S.


80 Gajewski TF, Meng Y, Harlin H: Immune suppression in the tumor microenviron-


83 Hiltbold EM, Ciborowski P, Finn OJ: Natu-

84 Hiltbold EM, Alter MD, Ciborowski P, Finn OJ: Presentation of MUC1 tumor antigen by class I MHC and CD8+ T cell responses to multiple tumor an-


